# ALX Oncology (ALXO) — Analyst Forecast

ALXO · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/alxo/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 6 | 1 | 0 | 7 |

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Mar 19, 2026 | Wells Fargo | Initiated Coverage | Overweight | $5.00 |
| Mar 10, 2026 | HC Wainwright & Co. | Maintained | Buy | $4.00 |
| Feb 5, 2026 | Piper Sandler | Maintained | Overweight | $4.00 |
| May 21, 2025 | UBS | Maintained | Buy | $1.00 |
| May 9, 2025 | HC Wainwright & Co. | Maintained | Buy | $2.00 |
| Mar 7, 2025 | HC Wainwright & Co. | Maintained | Buy | $5.00 |
| Mar 7, 2025 | Stifel | Maintained | Hold | $1.50 |
| Mar 6, 2025 | Jefferies | Upgraded | Hold → Buy | $3.00 |
| Mar 6, 2025 | Piper Sandler | Maintained | Overweight | $9.00 |
| Jan 27, 2025 | UBS | Maintained | Buy | $2.20 |
| Jan 24, 2025 | HC Wainwright & Co. | Maintained | Buy | $5.00 |
| Jan 24, 2025 | Cantor Fitzgerald | Maintained | Overweight | — |
| Dec 19, 2024 | Jefferies | Downgraded | Buy → Hold | $2.00 |
| Dec 18, 2024 | HC Wainwright & Co. | Maintained | Buy | $25.00 |
| Dec 18, 2024 | Cantor Fitzgerald | Maintained | Overweight | — |
| Nov 12, 2024 | Cantor Fitzgerald | Maintained | Overweight | — |
| Aug 16, 2024 | UBS | Maintained | Buy | $4.00 |
| Aug 13, 2024 | HC Wainwright & Co. | Maintained | Buy | $25.00 |
| Aug 12, 2024 | Cantor Fitzgerald | Maintained | Overweight | — |
| Aug 9, 2024 | Stifel | Maintained | Hold | $3.00 |

## Frequently Asked Questions

### Is ALXO a buy, sell, or hold?

Analysts covering ALX Oncology currently average a Buy rating: 6 buy, 1 hold and 0 sell, from 7 analysts. Ratings reflect analyst opinion, not investment advice.

### What is the latest analyst rating on ALXO?

On Mar 19, 2026, Wells Fargo initiated coverage of ALX Oncology at Overweight with a price target of $5.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).